San Donato Hospital
CAR T-cell therapy in Italy typically costs from $350,000 to $500,000 for the full clinical pathway. The final price depends on the specific drug product, duration of mandatory hospital monitoring, and management of potential side effects. Patients save approximately 33% compared to the US, where this treatment averages $525,000. Most Italian protocols include cell collection, laboratory manufacturing, and specialized inpatient care in Milan or Rome.
Bookimed Expert Insight: Choosing a research-heavy center like San Raffaele in Milan provides access to world-renowned hematologists like Prof. Fabio Ciceri. This clinic, recognized by Newsweek as one of the World's Best Hospitals, offers CAR T-cell therapy starting around $140,150. While this base price covers the essential procedure, staying in an IRCCS-accredited facility ensures the highest standards for managing complex genetic and immune-related cases.
Why choose Italy for CAR T-cell therapy?
Access advanced CAR T-cell therapy solutions in trusted clinics .
| Italy | Turkey | Austria | |
| CAR T-cell therapy | from $350,000 | from $150,000 | from $350,000 |
No hidden fees – just official clinic prices. Pay at the clinic for CAR T-cell therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in CAR T-cell therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your CAR T-cell therapy journey.
Day 1
Day 2 - Day 3
Day 4
Day 5 - Day 12
Day 13
Day 14 - Day 20
Week 3 - Week 4
Week 5 onwards
Please note that each case is individual. This timeline may vary based on your personal health condition and the specifics of your treatment plan.
Principal Investigator in CAR T-cell therapy clinical trials – Professor Ciceri leads San Raffaele's Hematology and Bone Marrow Transplantation Unit.
Written by Anna Leonova
CAR T-cell therapy is available in Italy as a standard treatment for relapsed or refractory hematological malignancies like lymphoma and leukemia. The Italian Medicines Agency (AIFA) regulates these therapies, which are primarily delivered through specialized IRCCS-accredited research hospitals and university clinics.
Bookimed Expert Insight: While northern Italy clinics like San Raffaele handle the highest patient volumes, data shows a trend where centers in southern Italy, such as Cardarelli Hospital in Naples, may offer faster navigation through administrative bureaucracy. Patients should compare wait times across regions, as northern hubs often face higher demand despite having more facilities.
Patient Consensus: Seeking treatment early is vital as intensive prior chemotherapy can impact eligibility. Patients frequently note that the pre-approval process is rigorous and may require several months of waiting.
Eligibility for CAR T-cell therapy in Italy requires patients to have relapsed or refractory hematological cancers. Candidates must fail at least two prior lines of systemic therapy. The Italian Medicines Agency governs access through specialized hub centers like San Raffaele in Milan.
Bookimed Expert Insight: While Italy follows European Medicines Agency standards, the Italian Medicines Agency often sets stricter age caps. Professor Fabio Ciceri at San Raffaele leads critical cell therapy trials that may offer earlier access. Patients often wait 3–6 months for manufacturing, so early referral to a hub is vital.
Patient Consensus: Many find the approval process rigorous and sometimes describe it as a lottery. Moving quickly between treatment lines is essential to remain healthy enough for the manufacturing period.
Italy's national healthcare system (Servizio Sanitario Nazionale) fully covers CAR T-cell therapy for eligible patients. The Italian Medicines Agency (AIFA) grants these treatments innovation status, meaning public funding applies at authorized hematology centers for specific relapsed or refractory B-cell malignancies and multiple myeloma.
Bookimed Expert Insight: While Italy offers full public coverage, the concentration of authorized centers in Lombardy and Lazio creates significant geographic disparities. Patients often choose San Raffaele because it combines IRCCS research accreditation with massive clinical volume, serving 300,000 patients annually. This helps navigate the complex AIFA drug registry requirements faster than smaller regional hospitals.
Patient Consensus: Patients emphasize that while treatment is free for citizens, the approval process can take 6 months. Many suggest starting the eligibility verification early at AIFA-approved centers to manage the 3-to-12 month waiting periods effectively.
Italy is a global leader in CAR T-cell therapy, with San Raffaele in Milan and Bambino Gesù Children Hospital in Rome serving as primary hubs. These AIFA-authorized centers specialize in cell and gene therapy clinical trials for adult hematology and pediatric neuroblastoma.
Bookimed Expert Insight: Data shows San Raffaele maintains a unique position by integrating world-first stem cell breakthroughs with CAR-T delivery. While many centers offer standard protocols, Milan's IRCCS-accredited facilities manage significantly higher patient volumes. This concentrated experience often leads to more robust multidisciplinary follow-up for complex immune responses.
Accessing CAR T-cell therapy in Italy is hindered by uneven geographic distribution of centers, complex regional reimbursement processes, and strict eligibility criteria. While AIFA-approved, 70% of qualified clinics are concentrated in four northern and central regions, leaving five southern regions without local access.
Bookimed Expert Insight: While standard CAR T pathways involve long waits, Milan remains the strategic choice for international and local patients. Clinics like San Raffaele combine massive clinical research with high-volume hematology departments. Their role in gene therapy trials often provides earlier access to technology than smaller regional centers.
Patient Consensus: Patients report that while public coverage exists, the 6 to 12-month wait times often necessitate early involvement of advocacy groups. Most recommend securing complete treatment documentation immediately to expedite the complex reimbursement appeals process.